Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4456-4465

  Messmer, Michelle Nicole ^a   Pasmowitz, Joshua ^a   Kropp, Laura Elizabeth ^b   Watkins, Simon C ^a   Binder, Robert Julian ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; CHAPERONE; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL DAMAGE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS PRESENTATION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SENTINEL LYMPH NODE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD11B; ANTIGENS, NEOPLASM; CELL LINE; HEAT-SHOCK PROTEINS; IMMUNIZATION; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; LYMPH NODES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR CHAPERONES; NEOPLASMS;

EID: 84885439416     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300827     Document Type: Article

References (54)

1. Srivastava, P. K., H. Udono, N. E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93-98.
2. Binder, R. J., and P. K. Srivastava. 2004. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl. Acad. Sci. USA 101: 6128-6133.
3. Mo, A., C. Musselli, H. Chen, J. Pappas, K. Leclair, A. Liu, R. M. Chicz, A. Truneh, S. Monks, D. L. Levey, and P. K. Srivastava. 2011. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 29: 8530-8541.
4. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA 83: 3407-3411.
5. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120.
6. Testori, A., J. Richards, E. Whitman, G. B. Mann, J. Lutzky, L. Camacho, G. Parmiani, G. Tosti, J. M. Kirkwood, A. Hoos, et al; C-100-21 Study Group. 2008. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 26: 955-962.
7. Wood, C., P. Srivastava, R. Bukowski, L. Lacombe, A. I. Gorelov, S. Gorelov, P. Mulders, H. Zielinski, A. Hoos, F. Teofilovici, et al; C-100-12 RCC Study Group. 2008. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372: 145-154.
8. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-Associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 1391-1396.
9. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152: 5398-5403.
10. Basu, S., and P. K. Srivastava. 1999. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor-And peptide-specific immunity. J. Exp. Med. 189: 797-802.
11. Wang, X. Y., L. Kazim, E. A. Repasky, and J. R. Subjeck. 2001. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166: 490-497.
12. Binder, R. J., D. K. Han, and P. K. Srivastava. 2000. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1: 151-155.
13. Basu, S., R. J. Binder, T. Ramalingam, and P. K. Srivastava. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 303-313.
14. Matsutake, T., T. Sawamura, and P. K. Srivastava. 2010. High efficiency CD91-And LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun. 10: 7.
15. Pawaria, S., and R. J. Binder. 2011. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2: 521.
16. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, and P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12: 1539-1546.
17. Pawaria, S., M. N. Messmer, Y. J. Zhou, and R. J. Binder. 2011. A role for the heat shock protein-CD91 axis in the initiation of immune responses to tumors. Immunol. Res. 50: 255-260.
18. Houlihan, J. L., J. J. Metzler, and J. S. Blum. 2009. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells. J. Immunol. 182: 7451-7458.
19. Ichiyanagi, T., T. Imai, C. Kajiwara, S. Mizukami, A. Nakai, T. Nakayama, and H. Udono. 2010. Essential role of endogenous heat shock protein 90 of dendritic cells in antigen cross-presentation. J. Immunol. 185: 2693-2700.
20. Udono, H., D. L. Levey, and P. K. Srivastava. 1994. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci. USA 91: 3077-3081.
21. Binder, R. J., K. M. Anderson, S. Basu, and P. K. Srivastava. 2000. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J. Immunol. 165: 6029-6035.
22. Strbo, N., S. Pahwa, M. A. Kolber, L. Gonzalez, E. Fisher, and E. R. Podack. 2010. Cell-secreted Gp96-Ig-peptide complexes induce lamina propria and intraepithelial CD8+ cytotoxic T lymphocytes in the intestinal mucosa. Mucosal Immunol. 3: 182-192.
23. Heath,W. R., G. T. Belz, G. M. Behrens, C. M. Smith, S. P. Forehan, I. A. Parish, G. M. Davey, N. S. Wilson, F. R. Carbone, and J. A. Villadangos. 2004. Crosspresentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199: 9-26.
24. Liu, K., and M. C. Nussenzweig. 2010. Origin and development of dendritic cells. Immunol. Rev. 234: 45-54.
25. Wang, S., L. Qiu, G. Liu, Y. Li, X. Zhang, W. Jin, G. F. Gao, X. Kong, and S. Meng. 2011. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. Vaccine 29: 6342-6351.
26. Navaratnam, M., M. S. Deshpande, M. J. Hariharan, D. S. Zatechka, Jr., and S. Srikumaran. 2001. Heat shock protein-peptide complexes elicit cytotoxic Tlymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 19: 1425-1434.
27. Chandawarkar, R. Y., M. S. Wagh, and P. K. Srivastava. 1999. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J. Exp. Med. 189: 1437-1442.
28. Chandawarkar, R. Y., M. S. Wagh, J. T. Kovalchin, and P. K. Srivastava. 2004. Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int. Immunol. 16: 615-624.
29. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186: 1315-1322.
30. Shastri, N., and F. Gonzalez. 1993. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol. 150: 2724-2736.
31. Adorini, L., J. Moreno, F. Momburg, G. J. Hämmerling, J. C. Guéry, A. Valli, and S. Fuchs. 1991. Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 174: 945-948.
32. Binder, R. J., M. L. Harris, A. Ménoret, and P. K. Srivastava. 2000. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J. Immunol. 165: 2582-2587.
33. Hanson, H. L., D. L. Donermeyer, H. Ikeda, J. M. White, V. Shankaran, L. J. Old, H. Shiku, R. D. Schreiber, and P. M. Allen. 2000. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13: 265-276.
34. Banerjee, P. P., D. S. Vinay, A. Mathew, M. Raje, V. Parekh, D. V. Prasad, A. Kumar, D. Mitra, and G. C. Mishra. 2002. Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule. J. Immunol. 169: 3507-3518.
35. Eriksson, C., S. Rantapää-Dahlqvist, and K. G. Sundqvist. 2010. T-cell expression of CD91-A marker of unresponsiveness to anti-TNF therapy in rheumatoid arthritis. APMIS 118: 837-845.
36. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rössner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92.
37. Singh-Jasuja, H., R. E. Toes, P. Spee, C. Münz, N. Hilf, S. P. Schoenberger, P. Ricciardi-Castagnoli, J. Neefjes, H. G. Rammensee, D. Arnold-Schild, and H. Schild. 2000. Cross-presentation of glycoprotein 96-Associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 191: 1965-1974.
38. Binder, R. J., N. E. Blachere, and P. K. Srivastava. 2001. Heat shock proteinchaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem. 276: 17163-17171.
39. Noessner, E., R. Gastpar, V. Milani, A. Brandl, P. J. Hutzler, M. C. Kuppner, M. Roos, E. Kremmer, A. Asea, S. K. Calderwood, and R. D. Issels. 2002. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J. Immunol. 169: 5424-5432.
40. Tobian, A. A., D. H. Canaday, W. H. Boom, and C. V. Harding. 2004. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J. Immunol. 172: 5277-5286.
41. Robert, J., T. Ramanayake, G. D. Maniero, H. Morales, and A. S. Chida. 2008. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J. Immunol. 180: 3176-3182.
42. Villadangos, J. A., and W. R. Heath. 2005. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin. Immunol. 17: 262-272.
43. Romani, N., B. E. Clausen, and P. Stoitzner. 2010. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol. Rev. 234: 120-141.
44. Gray, E. E., and J. G. Cyster. 2012. Lymph node macrophages. J. Innate Immun. 4: 424-436.
45. Watkins, S. C., and R. D. Salter. 2005. Functional connectivity between immune cells mediated by tunneling nanotubules. Immunity 23: 309-318.
46. Blachère, N. E., R. B. Darnell, and M. L. Albert. 2005. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 3: e185.
47. Asano, K., A. Nabeyama, Y. Miyake, C. H. Qiu, A. Kurita, M. Tomura, O. Kanagawa, S. Fujii, and M. Tanaka. 2011. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-Associated antigens. Immunity 34: 85-95.
48. Delamarre, L., M. Pack, H. Chang, I. Mellman, and E. S. Trombetta. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307: 1630-1634.
49. Oura, J., Y. Tamura, K. Kamiguchi, G. Kutomi, H. Sahara, T. Torigoe, T. Himi, and N. Sato. 2011. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells. Int. Immunol. 23: 223-237.
50. Imai, T., Y. Kato, C. Kajiwara, S. Mizukami, I. Ishige, T. Ichiyanagi, M. Hikida, J. Y. Wang, and H. Udono. 2011. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl. Acad. Sci. USA 108: 16363-16368.
51. Kato, Y., C. Kajiwara, I. Ishige, S. Mizukami, C. Yamazaki, S. Eikawa, K. Kakimi, and H. Udono. 2012. HSP70 and HSP90 differentially regulate translocation of extracellular antigen to the cytosol for cross-presentation. Autoimmune Dis. 2012: 745962.
52. Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15: 821-850.
53. Ishii, T., H. Udono, T. Yamano, H. Ohta, A. Uenaka, T. Ono, A. Hizuta, N. Tanaka, P. K. Srivastava, and E. Nakayama. 1999. Isolation of MHC class Irestricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol. 162: 1303-1309.
54. Li, C., M. R. Buckwalter, S. Basu, M. Garg, J. Chang, and P. K. Srivastava. 2012. Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proc. Natl. Acad. Sci. USA 109: 17543-17548.